Abstract:BackgroundCD137 (4-1BB) is a powerful T cell co-stimulatory molecule belonging to the TNF receptor superfamily, which promotes cytotoxic T cell survival and memory formation upon CD137L ligation. CD137 has become an attractive immuno-oncology therapeutic target with multiple agonistic antibodies in clinical trials, including urelumab and utomilumab, with promising response in combination with anti-PD1 immunotherapies such as nivolumab. Clinical applications of CD137 agonistic antibodies are hampered, however, … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.